Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin (Q45218162)
Jump to navigation
Jump to search
scientific article published in January 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin |
scientific article published in January 2005 |
Statements
1 reference
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin (English)
1 reference
De Leeuw I
1 reference
Vague P
1 reference
Selam JL
1 reference
Skeie S
1 reference
Lang H
1 reference
Draeger E
1 reference
Elte JW
1 reference
1 January 2005
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference